Genentech to restrict Avastin availability due to off-label use

10/11/2007 | Wall Street Journal, The · NYTimes.com

Genentech said it will halt the distribution of its cancer treatment Avastin to compounding pharmacies as more ophthalmologists recommend the drug's off-label use for wet age-related macular degeneration. The move is an attempt to promote Genentech's more-expensive eye drug Lucentis, which has lagged in sales, but Medicare says limiting distribution of the cancer drug could cost the system as much as $3 billion a year.

View Full Article in:

Wall Street Journal, The · NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC